MET Is a potential target across all papillary renal cell carcinomas: Result from a large molecular study of pRCC with CGH array and matching gene expression array

Clinical Cancer Research

Volumn 20, Issue 13, 2014, Pages 3411-3421

  Albiges, Laurence ^a   Guegan, Justine ^b,c   Le Formal, Audrey ^a   Verkarre, Virginie ^d   Rioux Leclercq, Nathalie ^j   Sibony, Mathilde ^e   Bernhard, Jean Christophe ^k   Camparo, Philippe ^f   Merabet, Zahira ^a   Molinie, Vincent ^g   Allory, Yves ^h   Orear, Cedric ^c   Couvé, Sophie ^a   Gad, Sophie ^a   Patard, Jean Jacques ^a,i   Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Bioinformatics Unit   (Spain)

^c Functional Genomics Unit   (Finland)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e HÔPITAL TENON   (France)

^f FOCH HOSPITAL   (France)

^g HÔPITAL SAINT JOSEPH   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ BICÊTRE HOSPITAL   (France)

^j UNIVERSITÉ DE RENNES 1   (France)

^k HÔPITAL SAINT ANDRÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA; SCATTER FACTOR RECEPTOR; CARRIER PROTEIN; PROTEIN BINDING;

ADULT; AGED; ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MET GENE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; ONCOGENE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; UPREGULATION; VERY ELDERLY; BIOLOGY; CANCER GRADING; CANCER STAGING; CLUSTER ANALYSIS; COPY NUMBER VARIATION; DNA SEQUENCE; EXON; GENE EXPRESSION PROFILING; GENETICS; KIDNEY TUMOR; MIDDLE AGED; MUTATION; PAPILLARY CARCINOMA; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CARRIER PROTEINS; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTATIONAL BIOLOGY; DNA COPY NUMBER VARIATIONS; EXONS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MET; SEQUENCE ANALYSIS, DNA;

EID: 84903843228     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2173     Document Type: Article

References (46)

1. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006;49: 798-805.
2. Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, Montironi R. 2009 update on the classification of renal epithelial tumors in adults. Int J Urol 2009;16: 432-43.
3. Delahunt B, Eble JN. Papillary renal cell carcinoma: aclinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997; 10: 537-44.
4. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 2001; 32: 590-5.
5. Allory Y, Ouazana D, Boucher E, Thiounn N, Vieillefond A. Papillary renal cell carcinoma. Prognostic value of morphological subtypes in a clinicopathologic study of 43 cases. Virchows Arch Int J Pathol 2003;442: 336-42.
6. Pignot G, Elie C, Conquy S, Vieillefond A, Flam T, Zerbib M, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 2007;69: 230-5.
7. Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res 2009;15: 1162-9.
8. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in thetyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68-73.
9. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18: 2343-50.
10. Salvi A, Marchina E, Benetti A, Grigolato P, De Petra G, Barlati S. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int J Oncol 2008;33: 271-6.
11. Lubensky IA, Schmidt L, Zhuang Z, Weirich G, Pack S, Zambrano N, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999;155: 517-26.
12. Diamond JR, Salgia R, Varella-Garcia M, Kanteti R, LoRusso PM, Clark JW, et al. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol 2013;31: e254-8.
13. Harshman LC, Choueiri TK. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J Sudbury Mass 2013;19: 316-23.
14. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4: 915-25.
15. Organ SL, Tsao M-S. An overview of the c-MET signaling pathway. Ther Adv Med Oncol 2011; 3: S7-19.
16. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013;31: 181-6.
17. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011; 29: 4789-95.
18. Go H, Jeon YK, Park HJ, Sung S-W, Seo J-W, Chung DH. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol 2010;5: 305-13.
19. Bottaro DP, Rubin JS, Faletto DL. Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251: 802-4.
20. Looyenga BD, Furge KA, Dykema KJ, Koeman J, Swiatek PJ, Giordano TJ, et al. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sei 2011;108: 1439-44.
21. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3: Article3.
22. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostat Oxf Engl 2004;5: 557-72.
23. Schmittgen TD, Zakrajsek BA. Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods 2000;46: 69-81.
24. Furge KA, Dykema KJ, Ho C, Chen X. Comparison of array-based comparative genomic hybridization with gene expression-based regional expression biases to identify genetic abnormalities in hepa-tocellular carcinoma. BMC Genomics 2005;6: 67.
25. Olivero M, Valente G, Bardelli A, Longati P, Ferrera N, Cracco C, et al. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer 1999;82: 640-3.
26. Steffens S, Janssen M, Roos FC, Becker F, Schumacher S, Seidel C, et al. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma-a multicentre study. Eur J Cancer 2012; 48: 2347-52.
27. Kim KH, You D, Jeong IG, Kwon T-W, Cho YM, Hong JH, et al. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus. BJU Int 2012;110: E673-8.
28. Bellmunt J, Dutcher J. Targeted therapies and the treatment of non-clear cell renal cell carcinoma. Ann Oncol 2013;24: 1730-40.
29. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Ural 2012;62: 1013-9.
30. Lee J-L, Ahn J-H, Lim HY, Park SH, Lee SH, Kim TM, et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol 2012;23: 2108-14.
31. Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 2013;24: 343-9.
32. Choi JS, Kim M-K, Seo JW, Choi Y-L, Kim DH, Chun YK, et al. MET expression in sporadic renal cell carcinomas. J Korean Med Sei 2006;21: 672-7.
33. Glukhova L, Lavialle C, Fauvet D, Chudoba I, Danglot G, Angevin E, et al. Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcinomas: ncreased copy number and overexpression of the MET proto-oncogene. Oncogene 2000;19: 754-61.
34. Dziadziuszko R, Wynes MW, Singh S, Asuncion BR, Ranger-Moore J, Konopa K, et al. Correlation between MET gene copy number by silver n situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 2012;7: 340-7.
35. Wilhelm M, Veltman JA, Olshen AB, Jain AN, Moore DH, Presti JC Jr, et al. Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res 2002;62: 957-60.
36. Monzon FA, Hagenkord JM, Lyons-Weiler MA, Balani JP, Parwani AV, Sciulli CM, et al. Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumors. Mod Pathol 2008;21: 599-608.
37. Matsuda D, Khoo SK, Massie A, Iwamura M, Chen J, Petillo D, et al. Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC. Cancer Lett 2008;272: 260-7.
38. Sanders ME, Mick R, Tomaszewski JE, Barr FG. Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma. Am J Pathol 2002;161: 997-1005.
39. Brunelli M, Eble JN, Zhang S, Martignoni G, Cheng L. Gains of chromosomes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: a fluorescent in situ hybridization study. Mod Pathol 2003;16: 1053-9.
40. Gunawan B, von Heydebreck A, Fritsch T, Huber W, Ringert R-H, Jakse G, et al. Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. Cancer Res 2003;63: 6200-5.
41. Balint I, Szponar A, Jauch A, Kovacs G. Trisomy 7 and 17 mark papillary renal cell tumours irrespectively of variation of the phenotype. J Clin Pathol 2009;62: 892-5.
42. Szponar A, Zubakov D, Pawlak J, Jauch A, Kovacs G. Three genetic developmental stages of papillary renal cell tumors: duplication of chromosome 1q marks fatal progression. Int J Cancer 2009;124: 2071-6.
43. Zhuang Z, Park WS, Pack S, Schmidt L, Vortmeyer AO, Pak E, et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 1998;20: 66-9.
44. Fischer J, Palmedo G, von Knobloch R, Bugert P, Prayer-Galetti T, Pagano F, et al. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal eel tumours. Oncogene 1998;17: 733-9.
45. Gunia S, Erbersdobler A, Hakenberg OW, Koch S, May M. C-MET is expressed in the majority of penile squamous cell carcinomas and correlates with polysomy-7 but is not associated with MET oncogene amplification, pertinent histopathologic parameters, or with cancer-specific survival. Pathol Res Pract 2013;209: 215-20.
46. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29: 4803-10.